Candela Corporation is launching the Vbeam Pro platform at the 2025 Annual Meeting of the American Society for Laser Medicine and Surgery (ASLMS) in Orlando, FL.
The Vbeam Pro is U.S. Food and Drug Administration (FDA)-cleared for use in pediatric patients and combines an advanced 595-nm pulsed dye laser with a 1064 nm Nd:YAG. The platform is designed to treat a broad spectrum of skin conditions, including rosacea, port-wine stains, acne, leg veins, spider veins, scars, benign pigmented lesions, wrinkles, warts, stretch marks, and photoaging. The Vbeam Pro laser can be used across all Fitzpatrick skin types (I–VI).
The platform also features optimized dye life and an enhanced user interface.
“Reinforcing Candela’s commitment to scientific rigor, the Vbeam Pro system underwent extensive clinical evaluation at leading dermatology practices across the United States,” says Konika Patel Schallen, MD, Senior Vice President of Clinical Operations and Medical Director at Candela, in a news release. “We put the platform through stringent testing, using it in busy clinical environments on a wide variety of skin types and conditions. We are excited about the feedback from our dermatology users on enhancing patient outcomes and treatment efficiency.”
“Building on Candela’s longstanding clinical leadership, the introduction of the Vbeam Pro system represents a major leap forward in the treatment of vascular and other skin conditions,” adds Geoffrey Crouse, Chief Executive Officer of Candela. “This milestone launch reflects our unwavering commitment to continuous innovation, rooted in proven science, consistent clinical outcomes, and trusted partnerships with both healthcare providers and patients.”
